Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Content zoeken bij Prinses Máxima Centrum
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Adjuvant ipilimumab in stage III melanoma: New landscape, new questions
Alexander M.M. Eggermont
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
peer review
15
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Adjuvant ipilimumab in stage III melanoma: New landscape, new questions'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Ipilimumab
100%
Stage III Melanoma
100%
Overall Survival
50%
Placebo
50%
Distant Metastasis-free Survival
33%
Targeted Agents
16%
High Risk
16%
Survival Rate
16%
Adjuvant Therapy
16%
Hazard Ratio
16%
Interferon-α (IFN-α)
16%
Cancer Treatment
16%
Immune-related
16%
Health-related Quality of Life
16%
New Treatment Options
16%
Quality of Life Assessment
16%
Melanoma
16%
Treatment Duration
16%
Patient's Will
16%
Risk of Death
16%
Node-positive
16%
Ongoing Trials
16%
European Organizations
16%
Free Survival
16%
Sentinel Lymph Node
16%
Melanoma Patients
16%
Completion Lymph Node Dissection
16%
Adverse Event Rates
16%
Global Health
16%
Treatment Landscape
16%
Access to New Drugs
16%
Going beyond
16%
Anti-programmed Cell Death Protein 1
16%
Medicine and Dentistry
Ipilimumab
100%
Melanoma
100%
Overall Survival
50%
Placebo
50%
Distant Metastasis Free Survival
33%
Adverse Event
16%
Survival Rate
16%
Hazard Ratio
16%
Cancer Treatment
16%
Quality of Life
16%
Adjuvant Therapy
16%
Arm
16%
Treatment Duration
16%
Retroperitoneal Lymph Node Dissection
16%
Sentinel Node
16%
Interferon
16%
Adjuvant
16%
Programmed Death 1 Receptor
16%
Immunity
16%
Nursing and Health Professions
Melanoma
100%
Ipilimumab
100%
Overall Survival
50%
Placebo
50%
Distant Metastasis Free Survival
33%
Malignant Neoplasm
16%
Quality of Life
16%
Survival Rate
16%
Hazard Ratio
16%
Treatment Duration
16%
Adverse Event
16%
Adjuvant Therapy
16%
Lymph Node Dissection
16%
Interferon
16%
Adjuvant
16%
Programmed Death 1 Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Ipilimumab
100%
Overall Survival
50%
Placebo
50%
Distant Metastasis Free Survival
33%
Malignant Neoplasm
16%
Survival Rate
16%
Adverse Event
16%
Interferon
16%
Adjuvant
16%
Programmed Death 1 Receptor
16%